Phylo’s AI Agents Could Make Biomedical Research Faster—Without Making It Less Rigorous

Overview: How Phylo’s AI-Driven Scientific Research Platform Transforms Biomedical Discovery

Phylo is an AI-driven scientific research platform that provides collaborative agents and an integrated workspace for biomedical research, supporting biologists as they investigate questions, synthesise evidence, and execute research workflows. It addresses a common bottleneck in life-sciences R&D: valuable scientific knowledge, data sources, computational methods, and experimental reasoning are often dispersed across tools and teams, making it hard to move efficiently from a research question to a well-supported, repeatable result.

The platform applies agentic AI to help clarify research requests, connect reasoning to a biology knowledge graph, and review outputs against traceable references. Its approach combines AI assistance with structured workflows, including pre-built workflows across the biopharma value chain and deterministic pipelines intended to make selected tasks reproducible. By bringing these capabilities into a unified research environment, Phylo can reduce the manual effort involved in coordinating information gathering, analysis, and workflow execution.

For research teams, this can speed progress from hypothesis to evidence-backed outputs while improving consistency in how analyses and research steps are documented and repeated. The practical value lies in shortening time spent on fragmented, repetitive research activities and giving scientists a more structured foundation for reviewing results, making decisions, and advancing biomedical discovery.

Last checked on September 8, 2026: Phylo remains active, with Biomni Lab expanding from its February 2026 launch through pharmaceutical collaborations with Ono and Chugai for agentic AI-enabled drug-discovery workflows.

What is Phylo?

Phylo develops Biomni Lab, an agentic AI platform for biomedical research and drug discovery that combines AI agents with more than 300 databases, software systems, and analytical tools in a single research environment. It is designed for biomedical researchers and R&D teams in academic laboratories, biotechnology companies, pharmaceutical organisations, and healthcare research settings, supporting work across areas such as disease biology, human genetics, single-cell analysis, target evaluation, experimental design, and computational analysis.

Its technical approach centres on orchestrating AI agents across heterogeneous biomedical resources and connecting them to proprietary research data within an organisation’s environment; Phylo also states that it maintains an open-source Biomni research project. The company reports a Ginkgo Bioworks case study in which more than 10 cell-painting and transcriptomic analyses produced publication-quality results validated by Ginkgo scientists, though independent clinical validation, regulatory clearance, and compliance certifications are not specified in the reviewed pages

Why Do Leading Healthcare Teams Trust Phylo?

• Phylo has announced collaborations with Ono Pharmaceutical and Chugai Pharmaceutical to deploy Biomni Lab in drug-discovery research workflows.

• Chugai’s planned deployment includes research areas such as single-cell analysis, human genetics, disease biology, and target evaluation, with proprietary data connected within Chugai’s environment.

• Ono Pharmaceutical reported that its researchers had adopted Biomni Lab and identified potential to accelerate routine discovery work; this is a partner statement rather than independent performance validation.

• Phylo announced a $13.5 million seed round in February 2026, co-led by Andreessen Horowitz and Menlo Ventures’ Anthology Fund with Anthropic.

• Phylo states that its scientific advisers include Carolyn Bertozzi, Feng Zhang, and Fabian Theis.

• The company originated the open-source Biomni project at Stanford and states that it will continue to maintain and support the open-source research project and its community.

• Phylo reports that Biomni has been adopted by tens of thousands of scientists across more than 7,000 research labs, biopharma companies, and healthcare organisations; this adoption figure is company-reported.

• Phylo reports a Ginkgo Bioworks case study in which more than 10 cell-painting and transcriptomic analyses generated publication-quality results validated by Ginkgo scientists; the finding is partner-validated and not presented as independent clinical evidence.

• Phylo states that Biomni Lab integrates more than 300 databases, software systems, and analytical tools into a single research environment.

• FDA clearance, CE marking, ISO certifications, HIPAA or GDPR alignment, and other formal compliance certifications were not specified in the reviewed Phylo announcements and partnership pages.